| Revue: | Revista médica de Chile |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000431093 |
| ISSN: | 0034-9887 |
| Autores: | Pulgar, Dahiana1 Yáñez, Nicolás1 Ortega, Francisco1 |
| Instituciones: | 1Universidad Católica del Maule, Facultad de Medicina, Talca. Chile |
| Año: | 2019 |
| Periodo: | Jul |
| Volumen: | 147 |
| Número: | 7 |
| Paginación: | 887-890 |
| País: | Chile |
| Idioma: | Español |
| Tipo de documento: | Artículo |
| Enfoque: | Analítico, descriptivo |
| Resumen en inglés | The use of systemic chemotherapy has survival and palliation benefits in oncological patients. Mortality at 30 days after the administration of systemic chemotherapy is considered as a quality and safety indicator of oncological patient care. The international mortality threshold is 5%, which is the figure used to compare institutions. Aim: To assess mortality at 30 days after the administration of ambulatory systemic chemotherapy in a regional referral center in adult cancer patients. Material and Methods: Retrospective observational study of patients receiving ambulatory systemic chemotherapy in the oncology service of a regional public hospital during 2018. The 30-day mortality rate was calculated. Demographic characteristics, baseline disease and the treatment received were recorded. Results: During the study period, 690 patients received ambulatory systemic chemotherapy. Chemotherapy was palliative in 76% of patients and 53% received a first line treatment. Seventeen (2.5%) died within 30 days of treatment administration. Nine deaths (52.9%) were definitely related to treatment and sepsis was the most frequent cause. Conclusions: Our mortality rates are similar to international data. This type of audit reviews local outcomes and identifies factors contributing to mortality aiming to improve standards of care |
| Disciplinas: | Medicina |
| Palabras clave: | Oncología, Farmacología, Terapéutica y rehabilitación, Cáncer, Quimioterapia, Antineoplásicos, Mortalidad |
| Keyword: | Oncology, Pharmacology, Therapeutics and rehabilitation, Cancer, Chemotherapy, Antineoplastic agents, Mortality |
| Texte intégral: | Texto completo (Ver HTML) |
